CASI Pharmaceuticals Receives Clinical Trial Application Approval From China's NMPA To Proceed With Phase 1/2 Study Of CID-103 In Immune Thrombocytopenia
Portfolio Pulse from Benzinga Newsdesk
CASI Pharmaceuticals has received approval from China's NMPA to proceed with a Phase 1/2 study of CID-103 for treating immune thrombocytopenia.
October 24, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CASI Pharmaceuticals has been approved by China's NMPA to start Phase 1/2 trials for CID-103, targeting immune thrombocytopenia. This regulatory approval is a positive step in the drug development process.
The approval from China's NMPA is a significant milestone for CASI Pharmaceuticals, as it allows the company to advance its clinical trials for CID-103. This progress is likely to be viewed positively by investors, potentially boosting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100